HK Inno N Corp
195940
Company Profile
Business description
HK Inno N Corp operates in the Ethical Drugs (ETC) and Health & Beauty (H&B) businesses. Key products in the ETC sector include K-Cap, Lovajet, and Akinzio, while key products in the H&B sector include Condition, Hogaesu, and B-Ones. The company operates in two segments: Pharmaceutical division; and Health and Beauty division. It generates maximum revenue from Pharmaceutical division. Geographically, it operates in Domestic and Foreign markets.
Contact
No. 239, Osongsaengmyeong 2-ro
Osong-eup, Heungdeok-gu
Chungcheongbuk-do
Cheongju-si
KORT: +82 3151764000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,703
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,200.77 | 274.33 | -0.52% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,135.07 | 414.79 | -1.56% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,710.17 | 18.84 | 0.14% |
| S&P 500 | 7,701.70 | 42.28 | -0.55% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |